DNLI FY2025 EPS Estimate Boosted by Cantor Fitzgerald

Denali Therapeutics Inc. (NASDAQ:DNLI) – Investment analysts at Cantor Fitzgerald upped their FY2025 earnings per share (EPS) estimates for shares of Denali Therapeutics in a report issued on Wednesday, May 7th. Cantor Fitzgerald analyst J. Schimmer now expects that the company will post earnings of ($2.97) per share for the year, up from their prior estimate of ($3.04). Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.71) per share.

A number of other research analysts have also issued reports on DNLI. HC Wainwright reduced their price objective on Denali Therapeutics from $80.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Denali Therapeutics in a report on Tuesday, February 11th. They issued a “buy” rating and a $31.00 price objective on the stock. Bank of America reduced their target price on shares of Denali Therapeutics from $30.00 to $28.00 and set a “buy” rating for the company in a research note on Monday, March 10th. William Blair upgraded shares of Denali Therapeutics to a “strong-buy” rating in a research note on Thursday, April 24th. Finally, Wedbush reduced their price objective on Denali Therapeutics from $32.00 to $30.00 and set an “outperform” rating for the company in a research report on Wednesday. One investment analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $33.79.

Denali Therapeutics Stock Down 0.3 %

DNLI opened at $14.39 on Friday. The company’s 50-day moving average price is $14.27 and its 200 day moving average price is $20.08. Denali Therapeutics has a fifty-two week low of $10.57 and a fifty-two week high of $33.33. The firm has a market cap of $2.09 billion, a price-to-earnings ratio of -5.21 and a beta of 1.49.

Denali Therapeutics (NASDAQ:DNLI) last issued its earnings results on Tuesday, May 6th. The company reported ($0.78) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.07). During the same period in the prior year, the business earned ($0.68) EPS.

Institutional Trading of Denali Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in DNLI. Norges Bank acquired a new position in Denali Therapeutics in the fourth quarter worth approximately $21,717,000. Vanguard Group Inc. grew its holdings in shares of Denali Therapeutics by 7.6% in the 4th quarter. Vanguard Group Inc. now owns 12,021,230 shares of the company’s stock worth $244,993,000 after acquiring an additional 843,996 shares during the last quarter. Polar Asset Management Partners Inc. grew its holdings in shares of Denali Therapeutics by 1,240.9% in the 4th quarter. Polar Asset Management Partners Inc. now owns 551,092 shares of the company’s stock worth $11,231,000 after acquiring an additional 509,992 shares during the last quarter. Balyasny Asset Management L.P. lifted its holdings in shares of Denali Therapeutics by 822.4% during the fourth quarter. Balyasny Asset Management L.P. now owns 416,074 shares of the company’s stock valued at $8,480,000 after purchasing an additional 370,966 shares during the last quarter. Finally, Millennium Management LLC boosted its position in shares of Denali Therapeutics by 571.8% in the 4th quarter. Millennium Management LLC now owns 404,224 shares of the company’s stock valued at $8,238,000 after purchasing an additional 344,056 shares during the period. 92.92% of the stock is currently owned by institutional investors.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.